Department of Interventional Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China.
Diagn Pathol. 2013 Jun 17;8:95. doi: 10.1186/1746-1596-8-95.
The association between Methylenetetrahydrofolate reductase (MTHFR) Ala222Val (rs1801133) has been implicated to alter the risk of bladder cancer, but the results are controversial.
A comprehensive databases of Pubmed, Embase, Web of Science, and the Chinese Biomedical Database (CBM) were searched for case-control studies investigating the association between MTHFR Ala222Val polymorphism and bladder cancer susceptibility. Odds ratios (OR) and 95% confidence intervals (95%CI) were used to assess this possible association. A χ2-based Q-test was used to examine the heterogeneity assumption. Begg's and Egger's test were used to examine the potential publication bias. The leave-one-out sensitivity analysis was conducted to determine whether our assumptions or decisions have a major effect on the results of the review. Statistical analysis was performed with the software program Stata 12.0.
A total of 15 independent studies were identified, including 3,570 cases and 3,926 controls. Our analysis suggested that Ala222Val was not associated with bladder cancer risk in overall population under additive model (OR=0.96, 95%CI=0.76-1.21, P=0.731), dominant model (OR=1.00, 95%CI=0.87-1.15, P=0.975), recessive model (OR=0.92, 95%CI=0.79-1.07, P=0.279), and Ala allele versus Val allele (OR=0.96, 95%CI=0.86-1.07, P=0.427). In the subgroup analysis stratified by ethnicity and sources of controls, there were also no significant associations detected among different descent populations, population-based studies and hospital-based studies.
This meta-analysis showed the evidence that MTHFR Ala222Val polymorphism was not contributed to the development of bladder cancer.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2117182849994994.
亚甲基四氢叶酸还原酶（MTHFR）Ala222Val（rs1801133）的关联被认为改变了膀胱癌的风险，但结果存在争议。
通过检索 Pubmed、Embase、Web of Science 和中国生物医学文献数据库（CBM），我们对研究 MTHFR Ala222Val 多态性与膀胱癌易感性之间关联的病例对照研究进行了全面的文献检索。比值比（OR）和 95%置信区间（95%CI）用于评估这种可能的关联。基于 χ2 的 Q 检验用于检验异质性假设。Begg 和 Egger 检验用于检验潜在的发表偏倚。采用逐一剔除敏感性分析来确定我们的假设或决策是否对综述结果有重大影响。统计分析采用 Stata 12.0 软件程序进行。
共纳入 15 项独立研究，包括 3570 例病例和 3926 例对照。我们的分析表明，在总体人群中，Ala222Val 与膀胱癌风险无关，加性模型（OR=0.96，95%CI=0.76-1.21，P=0.731）、显性模型（OR=1.00，95%CI=0.87-1.15，P=0.975）、隐性模型（OR=0.92，95%CI=0.79-1.07，P=0.279）和 Ala 等位基因与 Val 等位基因（OR=0.96，95%CI=0.86-1.07，P=0.427）。在按种族和对照来源分层的亚组分析中，在不同血统人群、基于人群的研究和基于医院的研究中，也未发现显著关联。
本荟萃分析表明，MTHFR Ala222Val 多态性与膀胱癌的发生无关。
